CD33 and acute myeloid leukemia: The CD33 antibody-drug conjugate (ADC)—gemtuzumab ozogamicin (GO (CMA-676); Wyeth Laboratories, Mylotarg®, Philadelphia, PA, USA) is the next FDA approved drug for AML.